Table 2 Clinical response to pyrotinib in NSCLC patients with HER2 mutation

Best response, n (%)

Partial response

15 (19.2)

Stable disease

43 (55.1)

Progressive disease

20 (25.6)

Objective response rate, % (95% CI)

19.2 (11.2–30.0)

Disease control rate, % (95% CI)

74.4 (63.2–83.6)

Duration of response, median (95% CI)

9.9 (6.2–13.6)

Progression-free survival

Events, n (%)

50 (64.1)

Median, months (95% CI)

5.6 (2.8–8.4)

Overall survival

Events, n (%)

40 (51.3)

Median, months (95% CI)

10.5 (8.7–12.3)